Spotlight on Bicalutamide 150mg in the Treatment of Locally Advanced Prostate Cancer
Bicalutamide (Casodex®) is a competitive androgen receptor antagonist that inactivates androgen-regulated prostate cell growth and function, leading to cell apoptosis and inhibition of prostate cancer growth. It is administered orally as a once-daily dose. In the EU and a number of other countries, bicalutamide 150 mg/day is approved in men with locally advanced nonmetastatic prostate cancer as immediate therapy either as an adjuvant to active treatment or as monotherapy as an alternative to surgical or medical castration.
Combined analysis of the three trials that comprise the bicalutamide Early Prostate Cancer programme showed that bicalutamide administered in conjunction with standard care in men with locally advanced prostate cancer offers disease-free survival benefits over standard care alone and is generally well tolerated. Overall survival was improved to a greater extent in the subgroup of patients who received bicalutamide plus radiation therapy compared with radiation therapy alone. Men with localised prostate cancer do not benefit from the addition of bicalutamide to standard care. Combined analysis of two other studies in men with locally advanced prostate cancer show that bicalutamide monotherapy offers better tolerability and higher health-related quality-of-life scores for sexual interest and physical capacity compared with surgical or medical castration, while achieving disease-free and overall survival durations that were not significantly different. Thus, when treatment options are being evaluated, bicalutamide as adjuvant therapy or monotherapy should be considered as an alternative to other available hormonal therapies in men with locally advanced prostate cancer, especially in those who wish to maintain an active lifestyle.
KeywordsProstate Cancer Localise Prostate Cancer Advanced Prostate Cancer Bicalutamide Early Prostate Cancer
The full text article in Drugs 2006; 66 (6): 837–850 was reviewed by: P.-A. Abrahamsson, Department of Urology, Malmö University Hospital, Lund University, Malmö, Sweden; G. Di Lorenzo, Department of Endocrinology and Oncology and Medical Oncology-Prostate Cancer Center, University of Naples, Naples, Italy; A.V. Kaisary, Royal Free Hospital, London, UK; W. Oh, Lank Center for Genitourinary Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; P.F. Schellhammer, Department of Urology, East Virginia Medical School, Norfolk, Virginia, USA; P. Sieber, Urological Associates of Lancaster, Lancaster, Pennsylvania, USA.
- 14.Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. J Urol 2004; 172 (5 Pt 1): 1865–70PubMedCrossRefGoogle Scholar
- 15.Iversen P, Johansson J-E, Lodding P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004 Nov; 172 (5 Pt 1): 1871–6PubMedCrossRefGoogle Scholar
- 16.Iversen P, Johansson JE, Lodding P, et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006; 40(6): 441–52PubMedCrossRefGoogle Scholar
- 17.Wirth M, Tyrrell C, Delaere K, et al. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years’ follow-up. Prostate Cancer Prostatic Dis 2006 Nov 14, Epub ahead of printGoogle Scholar
- 19.Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998 Mar; 51: 389–96PubMedCrossRefGoogle Scholar